Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alphamab Oncology
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
The nation’s top drug regulator vows to adopt ICH’s guidelines on drug safety and efficacy, after dropping the industry a bombshell with the tightening of oncology drug clinical trials a week ago.
After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
- Large Molecule
- Other Names / Subsidiaries
- Alphamab Biopharmaceuticals Co., Ltd.
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
- Suzhou Alphamab Co., Ltd.